BeOne Medicines (ONC) Sets Q2 2026 Results Date As Undervaluation Narrative Builds
BeOne Medicines (ONC) is drawing investor attention after announcing plans to release its second quarter 2026 results on Wednesday, August 5, 2026, before markets open, followed by a management webcast.
See our latest analysis for BeOne Medicines.
BeOne Medicines' share price has risen 18.8% over the past month and 4.5% over the last week, while its 1 year total shareholder return of 5.9% and 3 year total shareholder return of around 5.8x suggest longer term holders have seen stronger momentum than recent quarterly moves, despite a small 1 day pullback.
If this oncology update has your attention, it could be a good moment to scan for other opportunities in the sector using our screener of 39 healthcare AI stocks
After BeOne Medicines' recent share price jump, the stock still sits at a sizeable discount to both analyst targets and intrinsic estimates. Is the market rightly cautious about its oncology pipeline and earnings profile, or overly skeptical?
Most Popular Narrative: 24.3% Undervalued
BeOne Medicines' most followed narrative pegs fair value near $412 per share, comfortably above the last close of $312.02, and builds that gap on detailed earnings and cash flow assumptions discounted at 7.1%.
The analysts have a consensus price target of $412.35 for BeOne Medicines based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you would need to believe that by 2029, revenues will be $8.5 billion, earnings will come to $1.6 billion, and it would be trading on a PE ratio of 35.3x, assuming you use a discount rate of 7.1%.
Want to understand why this narrative treats BeOne Medicines like a high growth compounder? The story leans heavily on brisk revenue expansion, sharply higher margins and a premium future earnings multiple. Curious which of those levers does the hardest work in the model and how much headroom it leaves against the current $312 share price? The full narrative breaks down those moving parts in plain numbers.
Result: Fair Value of $412 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this BeOne Medicines narrative could be challenged if BRUKINSA or sonrotoclax underperform against competitors, or if regulatory and pricing pressures squeeze profitability more than expected.
Find out about the key risks to this BeOne Medicines narrative.
Another View: Multiples Paint A Tougher Picture For BeOne Medicines
While the narrative and fair value workup suggest BeOne Medicines is 24.3% undervalued, its current P/E of 67.6x tells a different story. That is far above the US Biotechs industry at 17.3x, the peer average at 31.5x, and even the fair ratio of 35.8x. This spread implies meaningful valuation risk if sentiment cools.
For investors weighing these conflicting signals, the key question is whether the earnings and pipeline expectations behind that premium are strong enough to keep the market from drifting back toward the fair ratio or closer to sector norms.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With BeOne Medicines presenting both upside potential and clear concerns, it makes sense to move quickly, review the data yourself, and decide how the trade off looks in your portfolio using our breakdown of 4 key rewards and 1 important warning sign
Looking for more ideas beyond BeOne Medicines?
If BeOne Medicines has sharpened your focus, do not stop here. Use the Simply Wall St screener to uncover more opportunities that could suit your approach.
- Target dependable income streams by reviewing companies in the 8 dividend fortresses.
- Spot potential value opportunities early by scanning the screener containing 20 high quality undiscovered gems.
- Prioritise resilience by filtering for companies in the 84 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com